Serotonin

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Drew Barrymore Announces She’s the New Brand Ambassador for Dr. Kellyann's Breakthrough Perimenopause and Menopause Formula

Retrieved on: 
Thursday, February 29, 2024

Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.

Key Points: 
  • Barrymore has been struggling with perimenopause symptoms for more than a year now, and says this product has changed her life.
  • The influential voice of Drew Barrymore is helping more women than ever to feel comfortable and empowered to take control of their hormones, in a safe and natural way during perimenopause and menopause.
  • Dr. Kellyann and Drew Barrymore teamed up after Drew tried Dr. Kellyann &ME Peri + Menopause for 3 months and had incredible results.
  • To learn more about Dr. Kellyann &ME Peri + Menopause visit drkellyann.com or join the menopause conversation by following @drkellyannpetrucci across social.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

Seasonal Affective Disorder: Shedding Light on the Winter Blues with AltaPointe Health

Retrieved on: 
Tuesday, February 27, 2024

MOBILE, Ala., Feb. 26, 2024 /PRNewswire/ -- As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD). SAD is a type of depression that typically occurs when exposure to sunlight is limited.

Key Points: 
  • As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD).
  • MOBILE, Ala., Feb. 26, 2024 /PRNewswire/ -- As winter settles in and daylight hours diminish, many individuals find themselves grappling with a condition known as Seasonal Affective Disorder (SAD).
  • "If you have Seasonal Affective Disorder, it can cause you to be depressed up to 40% of the year."
  • Light therapy, which involves exposure to a bright light that mimics natural sunlight, is a commonly prescribed treatment.

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Retrieved on: 
Wednesday, January 31, 2024

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Key Points: 
  • ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
    Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry.
  • The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
  • The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey.
  • At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression.

Relax'in Naturally Reinforces Mental Health

Retrieved on: 
Wednesday, January 31, 2024

FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Mental health has been in the spotlight in recent years. As conditions like anxiety and depression become more common and diagnosable, it's important for consumers to have options to address them based on the severity of each case. With milder mental health concerns, solutions like Relax'in can help naturally restore a sense of peace and balance to everyday life.

Key Points: 
  • With milder mental health concerns, solutions like Relax'in can help naturally restore a sense of peace and balance to everyday life.
  • With mental health concerns on the rise, it's important for consumers to have options.
  • Restoring mental health balance with a natural alternative like Relax'in can also help avoid harmful habits rooted in mental instability, such as excessive alcohol consumption and smoking.
  • This ensures that Relax'in provides genuine, powerful, and natural support for those with mental health concerns.

STNR Creations Launches Revolutionary Amanita Mushroom Gummies

Retrieved on: 
Thursday, January 18, 2024

ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- STNR Creations, a trailblazer in hemp-derived and natural wellness products, proudly introduces its latest breakthrough: Energizing Amanita Mushroom Gummies, aptly named 'Not Your Grandma's Portobellos.' Expertly crafted, these gummies present a novel fusion of Amanita Muscaria with a special blend of cannabinoids, offering a safe, legal, and invigorating microdosing experience. This pioneering combination is designed to provide an unparalleled natural energy boost, opening new vistas in holistic health and well-being.

Key Points: 
  • ORLANDO, Fla., Jan. 18, 2024 /PRNewswire/ -- STNR Creations, a trailblazer in hemp-derived and natural wellness products, proudly introduces its latest breakthrough: Energizing Amanita Mushroom Gummies, aptly named 'Not Your Grandma's Portobellos.'
  • Renowned for infusing innovation into the hemp industry with their 3 Gram Disposable vape device, STNR Creations now expands its horizons with the introduction of 'Not Your Grandma's Portobellos' Amanita Mushroom Gummies.
  • Shaun Province, Vice President of Sales at STNR Creations, states, "Our 'Not Your Grandma's Portobellos' Amanita Mushroom Gummies represent our dedication to fusing ancient wisdom with modern innovation.
  • The 'Not Your Grandma's Amanita Mushroom Gummies' are more than just a product launch; they signify a movement towards redefining natural supplements.

Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss

Retrieved on: 
Tuesday, January 16, 2024

Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.

Key Points: 
  • Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.
  • The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.
  • Olfactive Biosolutions biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules.
  • “Protenx is the culmination of years of work and the efforts of many Olfactive Biosolutions dedicated scientists,” said Dr. William Harries, the company’s chief scientist.

Clearmind Medicine Completed Type A Meeting with the FDA

Retrieved on: 
Wednesday, January 10, 2024

"We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Key Points: 
  • "We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • The active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.